Holen Sie sich die Stockscreener-App
4.68
0.00%
0.02
Schlusskurs vom Vortag:
$4.70
Offen:
$4.67
24-Stunden-Volumen:
10,780
Relative Volume:
0.10
Marktkapitalisierung:
$15.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.68M
KGV:
-0.3954
EPS:
-11.8364
Netto-Cashflow:
$-30.65M
1W Leistung:
-3.69%
1M Leistung:
-16.37%
6M Leistung:
-73.95%
1J Leistung:
+985.45%
1-Tages-Spanne:
$4.60
$4.73
1-Wochen-Bereich:
$4.42
$4.92
52-Wochen-Spanne:
$0.3502
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.68 | 15.04M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
519.60 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.30 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.45 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.66 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.15 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-04-21 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-03-31 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-10 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive
PASG Forecast — Price Target — Prediction for 2027 - TradingView
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Remix to enter Nasdaq through Passage Bio reverse merger - The Pharma Letter
Passage Bio and Remix Therapeutics Announce Merger to Advance RNA-Targeted Cancer Therapies with $100M Financing – Minichart - Minichart
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Asianet Newsable
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Passage Bio Shares Slide on Merger With Remix Therapeutics - Moomoo
Passage Bio And Remix Therapeutics Announce Merger Agreement - TradingView
Passage Bio (PASG) Slides 3.9% as Momentum Falters Near Key SupportWave Truncation - dars.gov.et
Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M - Stock Titan
Passage Bio to merge with Remix Therapeutics in all-stock deal - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement - Moomoo
PASG Stock Slumps 16% After-HoursWhat's Driving The Selloff? - Mena FN
Remix Therapeutics, Inc. entered into a definitive merger agreement to acquire Passage Bio, Inc. in a reverse merger transaction for approximately $230 million. - marketscreener.com
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Passage Bio Inc (PASG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sea Limited’s Shopee Order Growth Reinforces E-Commerce MomentumEarnings Momentum Score - newsline.com
PRS Q1 2026 Earnings: Solid EPS Beat Driven by Core OperationsEarnings Deceleration Risk - newsline.com
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Gartner (IT) Q1 2026 Earnings: EPS Surprises to the Upside Despite Modest Stock PullbackRevenue Recognition Risk - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Passage Bio Inc-Aktie (PASG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chou William | PRESIDENT AND CEO |
Jan 08 '26 |
Sale |
18.44 |
4,076 |
75,159 |
6,524 |
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
0.82%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):